Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 3, 2010, Pages 354-360

  Socinski, Mark A ^a   Scappaticci, Frank A ^b   Samant, Meghna ^b   Kolb, Margaret M ^b   Kozloff, Mark F ^c,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GENENTECH INC   (United States)

^c Ingalls Memorial Hospital   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bevacizumab; Locally advanced; Metastatic; Metastatic disease; Non small cell lung cancer; Nonsquamous; Recurrent; Sunitinib

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; LIGAND; PACLITAXEL; SUNITINIB; VASCULOTROPIN RECEPTOR;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HEART LEFT VENTRICLE OVERLOAD; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77649322923     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c7307e     Document Type: Article

References (20)

1. Surveillance Epidemiology and End Results (SEER), National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed September 19, 2008.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:4539-4544.
3. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-934.
4. Genentech, Inc. Avastin® (Bevacizumab) [Package Insert.] South San Francisco, CA: Genentech, Inc., 2007.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
7. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res 2007;13:s4613-s4616.
8. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
9. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605.
10. Pfizer, Inc. Sutent® (Sunitinib) [Package Insert.] New York City, NY: Pfizer, Inc., 2006.
11. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656.
12. Genentech, Inc. Data-on-File. South San Francisco, CA: Genentech, Inc., 2008.
13. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439.
14. Rafii S, Avecilla S, Shmelkov S, et al. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann N Y Acad Sci 2003;996:49-60.
15. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-1234.
16. Mayer E, Kozloff M, Qamar R, et al. SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P)- bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results. Presented at: San Antonio Breast Cancer Conference 2009 San Antonio, TX:Abstract 3126.
17. Hanna NJ, von Pawel J, Reck M, et al. Carboplatin/paclitaxel with/ without sorafenib in chemonaive patients with stage IIIb-IV non-small cell lung cancer (NSCLC): interim analysis (ia) results from a randomized phase III trial (escape). Presented at: 1st European Lung Cancer Conference, 2008 Geneva Switzerland:Abstract 13.
18. Laurie SA, Arnold A, Shepherd FA, et al. Randomized, double-blind phase II trial of carboplatin 1 paclitaxel (C1P) with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, or placebo, in advanced nonsmall cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group. Abstract PD231 at European Society for Medical Oncology, 2008. Ann Oncol 2008;19(Suppl 8).
19. Cunningham D, Wong RP, D'haens G, et al. A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. J Clin Oncol 2008; 26(Suppl 15):Abstract 4028.
20. Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind Phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 2007;25 (Suppl 15):Abstract 1003.